Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Shares Issued (2016 - 2025)

CorMedix's Shares Issued history spans 13 years, with the latest figure at -$600.0 for Q4 2025.

  • For Q4 2025, Shares Issued rose 100.0% year-over-year to -$600.0; the TTM value through Dec 2025 reached $82.4 million, up 2745566.67%, while the annual FY2025 figure was $82.4 million, 2745566.67% up from the prior year.
  • Shares Issued for Q4 2025 was -$600.0 at CorMedix, down from $80.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $80.9 million in Q3 2025 and bottomed at -$41.3 million in Q4 2021.
  • The 5-year median for Shares Issued is $1.1 million (2025), against an average of $6.7 million.
  • The largest annual shift saw Shares Issued tumbled 326.75% in 2021 before it skyrocketed 2304.74% in 2022.
  • A 5-year view of Shares Issued shows it stood at -$41.3 million in 2021, then skyrocketed by 142.72% to $17.6 million in 2022, then crashed by 59.18% to $7.2 million in 2023, then tumbled by 285.73% to -$13.4 million in 2024, then soared by 100.0% to -$600.0 in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Shares Issued are -$600.0 (Q4 2025), $80.9 million (Q3 2025), and $1.1 million (Q2 2025).